Malte MD - Hookipa Pharma CEO Director

HOOK Stock  USD 2.48  0.16  6.90%   

CEO

Malte MD is CEO Director of Hookipa Pharma
Age 62
Address 350 Fifth Avenue, New York, NY, United States, 10118
Phone431 890 6360
Webhttps://www.hookipapharma.com

Hookipa Pharma Management Efficiency

The company has return on total asset (ROA) of (0.201) % which means that it has lost $0.201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4899) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma's management efficiency ratios could be used to measure how well Hookipa Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.53. The value of Return On Capital Employed is expected to slide to -0.86. At this time, Hookipa Pharma's Non Current Liabilities Other is quite stable compared to the past year. Change To Liabilities is expected to rise to about 4.5 M this year, although the value of Total Current Liabilities will most likely fall to about 25.1 M.
Hookipa Pharma currently holds 6.56 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Hookipa Pharma has a current ratio of 5.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hookipa Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 6 records

CEO Age

Amy MBATerns Pharmaceuticals
54
Daniel MBAAcumen Pharmaceuticals
54
Jeremy MBADay One Biopharmaceuticals
53
Paula RaganX4 Pharmaceuticals
54
Frank BeduAddoPDS Biotechnology Corp
59
Denise ScotsKnightMereo BioPharma Group
65
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company was incorporated in 2011 and is headquartered in New York, New York. Hookipa Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people. Hookipa Pharma (HOOK) is traded on NASDAQ Exchange in USA. It is located in 350 Fifth Avenue, New York, NY, United States, 10118 and employs 151 people. Hookipa Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Hookipa Pharma Leadership Team

Elected by the shareholders, the Hookipa Pharma's board of directors comprises two types of representatives: Hookipa Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hookipa. The board's role is to monitor Hookipa Pharma's management team and ensure that shareholders' interests are well served. Hookipa Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hookipa Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lukas Flatz, CoFounder
Klaus Orlinger, Chief Officer
Reinhard Kandera, CFO Director
Matthew Beck, Executive Relations
Mark Winderlich, Chief Officer
Joern Aldag, CEO Director
Marine Popoff, Communications Mang
Michael Szumera, Executive Communications
Roman Necina, Chief Officer
Prof MD, CoFounder
Andreas Bergthaler, CoFounder
Christine MBA, Chief Officer
Daniel Courtney, Corporate Secretary
Malte MD, CEO Director
Mary MBA, CFO VP

Hookipa Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hookipa Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.